Accure Medical is revolutionizing dermatology with the Accure Laser System, the first 1726nm platform to achieve both CE Mark certification and FDA clearance for the long-term treatment of mild to severe inflammatory acne vulgaris. Leveraging its patented treat-to-temperature technology, the system ensures consistent, safe, and effective results for all skin types. With rapid adoption across the US, Europe, Asia, and the Middle East, Accure is addressing a significant global need with its groundbreaking solution for acne treatment.

Visit website.

Acoustic Wave Cell Therapy (AWCT) is a clinical-stage company pioneering regenerative cellular therapy using low-intensity acoustic shockwaves or “Micro-energy Acoustic Pulses” (MAP). AWCT is poised to treat a broad spectrum of diseases by activating tissue-resident stem cells—beginning with female stress and urge urinary incontinence.

Visit website.

Aevice Health develops smart wearable stethoscopes for remote monitoring of respiratory diseases at home. Its acoustic sensors and proprietary AI capture and analyze lung sounds to support clinicians in long-term disease management and early detection of exacerbations, with the aim of improving patient outcomes and reducing hospital readmissions.

Visit website.

Agilis Robotics is redefining endoluminal surgery with flexible and miniaturized robotic arms that navigate complex anatomy with exceptional precision in both the urinary and gastrointestinal tract. Our proprietary technology seamlessly integrates with standard endoscopes, enabling shorter learning curves, safer and less invasive procedures with enhanced control and dexterity.

Visit website.

Ananda Devices is a biotech company based in Laval, Canada, specializing in advanced in vitro technologies for biomedical research. Its proprietary nano-organization platform enhances the precision and reproducibility of cellular assays, particularly in neuroscience, by enabling in vivo-like cellular structures with micron-level accuracy. The company offers customized solutions for various tissue types, including hair, skin, and muscle, and provides research services such as drug screening and neurotoxicity assays. Ananda Devices aims to reduce reliance on animal models and accelerate the development of human-relevant biological models.

Visit website.

Anaut is a Tokyo-based technology company that is passionate about using the power of AI to drive innovation in the healthcare industry. Our mission is to revolutionize surgery by developing AI precision mapping technology that can improve surgical outcomes and reduce the risk of complications. Our flagship product, Surgical Vision EUREKA, is a game-changing solution that has been specifically designed to support this mission. EUREKA uses cutting-edge algorithms and deep learning methodologies to achieve real-time precision mapping of the surgical field, allowing surgeons to navigate through complex anatomical structures with greater precision and accuracy. By leveraging the power of AI, we believe that we can transform the surgical landscape and provide better outcomes for patients around the world.

Visit website.

ANEUVO is developing a platform technology to treat chronic injuries and conditions that do not have cures through pharmaceutical approaches. The company’s lead product, ExaStim, is a noninvasive neuromodulation system that has received Breakthrough Device Designation from the U.S. FDA for treating paralysis in patients with spinal cord injury.

Visit website.

Annaida develops microscale Magnetic Resonance Spectroscopy (MRS) technology for non-invasive metabolic fingerprinting of small cell cultures. This innovation enables applications in life science, such as non-invasive pre-implantation embryo screening. Collaborating with top-ranked university laboratories and fertility clinics, Annaida is committed to expanding this platform’s impact in life science research and reproductive medicine.

Visit website.

​Aqua Medical has developed a vapor-based, through-the-endoscope ablation technology aimed at treating gastrointestinal diseases and preventing gastrointestinal cancers. The RF Vapor Ablation (RFVA) System utilizes heated water vapor delivered via endoscopic catheters to ablate targeted tissue. The system is designed to be fluoroscopy-free and offers a range of catheters to address various conditions throughout the GI tract.

Visit website.

The Atmo Gas Capsule is a unique ingestible capsule to provides unique insights into gut health and microbiome function. The device assesses the functional health of the GI system by means of measuring gaseous biomarkers as it passes through the GI system. Atmo Biosciences investigational device offers the potential to shed new light on disorders of the gut, beginning with highly prevalent motility disorders such as gastroparesis and slow transit constipation.

Visit website.

Azalea Vision is developing a solution for patients with conditions and disorders that increase sensitivity to light. The company's solution actively adapts and manages within a personalized contact lens. The lens will also be capable of compensating for refractive errors of the eye, such as astigmatism and myopia.

Visit website.

Berlin Heals is developing the C-MIC system, an implantable electroceutical device that delivers a constant, but minimal, electrical direct current that mimics the physiological electrical currents produced by the heart. The device is a near-curative treatment for patients with heart failure that propagates the reverse remodeling of cardiac muscle tissue to restore heart function and size, thereby reducing the symptoms of heart failure and improving quality of life.

Visit website.

Biobot Surgical develops Mona Lisa systems that are surgical robotic navigation platforms for transperineal prostate procedures. The Mona Lisa achieves millimetre accuracy in needle positioning by integrating the transperineal approach, advanced visualisation comprising MRI and ultrasound image fusion, and robotic precision with up to 8-degrees-of-freedom in motion. The Mona Lisa platform supports both diagnostic biopsies and therapeutic interventions, and has received regulatory approvals including FDA, CE, TGA, and HSA, with utilization in over 25,000 procedures worldwide.

Visit website.

​Biorithm is a medical technology company focused on advancing maternal and fetal care through digital health solutions. The company's flagship product, femom, is a remote monitoring platform that includes a clinical-grade fetal-maternal monitor, patient-reported symptom tracking, and connected point-of-care devices like blood pressure monitors and glucometers. The femom system enables clinicians to remotely assess the health of expectant mothers and their babies, facilitating early detection of complications and personalized care plans. Currently in the clinical investigation phase, femom aims to enhance continuity of care and empower patients and providers with data-driven insights.

Visit website.

Bloom Therapeutics is the newest company out of The Foundry, a prestigious medical device incubator in Menlo Park, California, USA. Bloom Therapeutics is working on a novel sustained release platform for obesity drugs (GLP-1, small molecules etc.) that allows for quarterly dosing with an optimized drug release profile that reduces side effects and improves patient compliance. The early preclinical results from Bloom Therapeutics has been highly encouraging showing stable, sustained release of obesity drugs for several months.

Bloom Therapeutics leverages strong R&D footprint in Singapore along with a seasoned management team out of The Foundry.

Visit website.

BrainSpace is developing a solution to simplify critical care in neurocritical patients. BrainSpace is committed to improving the way brain pressure is managed in patients recovering from stroke, traumatic brain injury, and neurosurgery. Currently patients requiring intracranial pressure management must be meticulously monitored and measured hourly by a nurse. The company has developed an automated monitoring solution as an alternative to the antiquated drainage monitoring relying on a manometer-based drain and blood pressure monitor that eliminates the hassle for patients and providers while improving the quality of data being captured for researchers and physicians.

Visit website.

Calla Lily Clinical Care is a women’s health-focused company pioneering the proprietary Callavid® platform for intravaginal drug delivery. Its first application targets IVF treatments, and will also position Callavid® as the world’s first drug–device combination product specifically aimed at miscarriage prevention.  Future indications include gynecological cancers and the delivery of live biotherapeutic products (LBPs) to reduce reliance on antibiotics and help combat antimicrobial resistance (AMR).  Calla Lily is redefining drug delivery in women’s health with precision, patient comfort, and global impact in mind. 

Visit website.

Ceroflo Limited, based in Galway, Ireland, is developing an innovative solution for the treatment and prevention of stroke, one of the world’s leading causes of death and disability. The company’s proprietary device, the SubMax™ Stent, is specifically designed to address intracranial atherosclerosis (ICAD)—a major contributor to stroke, particularly in Asia, where it accounts for up to 50% of cases. SubMax™ gently restores blood flow to the brain while minimizing the risks associated with earlier-generation devices. Founded by leaders from Neuravi and the broader Irish MedTech sector, Ceroflo combines deep clinical insight with proven commercialization and engineering expertise to tackle one of the most urgent unmet needs in global stroke care.

Visit website.

The TriPair™ Technology is a novel minimally invasive tricuspid repair solution designed to treat Tricuspid Regurgitation —a condition that affects millions globally, with the vast majority currently remaining untreated. TriPair™ simplifies transcatheter repair through an innovative edge-to-spacer approach, aiming to reduce procedural complexity and improve access to care. TriPair™  is designed to be simple, fast (procedure time under 30 minutes), and highly effective, empowering physicians in both established and underserved markets to treat patients who cannot be helped with existing technologies. Following a successful first-in-human trial, TriPair™ is now being prepared for evaluation in global feasibility studies across multiple continents.

visit website.

CorNeat Vision is committed to restoring sight and preventing blindness through novel ophthalmic implants. Our product portfolio targets corneal blindness, severe glaucoma, and high-risk scleral conditions.

CorNeat Vision's artificial cornea, synthetic scleral patch, and glaucoma drainage device leverage the unique features of its proprietary EverMatrix™ tissue-integration technology to provide long-lasting solutions that overcome the main challenges with the current standard of care.

Visit website.

Efemoral Medical is a clinical stage startup developing a next-generation drug-eluting bioresorbable scaffold for the treatment of PAD. Using a minimally invasive procedure, the Efemoral Vascular Scaffold System is inserted into the leg and expanded inside the artery to restore a channel for blood flow to the foot. The scaffold is strong enough to hold the vessel open, is flexible enough to accommodate the complex skeletal motion of the leg, and elutes a drug to prevent scarring inside the vessel which leads to the need for repeat procedures. The scaffold is naturally absorbed by the body over time, thus leaving behind no permanent implant.

Visit website.

Emovi’s KneeKG technology captures and analyzes 3D dynamic motion of the knee to generate objective functional data. It empowers digital surgery ecosystems to define personalized targets for restoring joint function and supports post-operative management—enabling surgical systems to be not only precise, but truly accurate and patient-specific, driving improved outcomes.

Visit website.

FoxEyes Corporation specializes in the research and development of robotic equipment and automated parts used in the medical field. We lead the way in surgical technologies by developing safer and more user-friendly robotic surgical equipment.

Visit website.

​GORYO Chemical has developed a series of activatable fluorescent probes, collectively known as Navigation Drugs (ND), designed to enhance the precision of cancer surgeries. These probes emit minimal fluorescence until they interact with specific enzymes overexpressed in cancerous tissues, allowing for the detection of minute cancer sites that are typically challenging to identify. Current applications include GCP-001 for breast cancer, GCP-002 for esophageal cancer, and GCP-003 for detecting pancreatic leaks. The technology aims to improve surgical outcomes by reducing the likelihood of residual cancer cells and minimizing the need for repeat surgeries.

Visit website.

Over 2 billion people suffer from chronic foot, knee, hip, or back pain—without knowing the problem starts below the ankle. Most treatments ignore the root cause: talotarsal joint instability. GraMedica fixes it at the source with a 20-minute, motion-preserving procedure that delivers 10X better outcomes—creating a scalable path to mobility, relief, and market growth.

Visit website.

• Spinem Robotics, developing a next-generation robotic and navigation platform for spine surgery.
• Extremis Robotics, focused on robotic and navigation solutions for foot and ankle surgery.
• Kyniska Robotics, creating the first robotic platform dedicated to sports medicine procedures.

Visit website.

Hemeo is a fast-paced and highly motivated start-up company in the US, with unique products and AI enabled technology designed for revolutionizing Blood Coagulation Management during Cardiac and other surgical procedures. Hemeo’s mission is helping physicians save lives, by providing them the critical Clinical Decision Software platform they need to “Improve the outcomes for millions, while saving billions”. Hemeo’s CEO, Lee DeGeer, leads a highly committed but coachable management team, with strong complementary expertise and a comprehensive industry specific ecosystem.

Visit website.

Hy2Care's vision is to support patients in the fight against osteoarthritis. The company's lead product, CartRevive, is a hydrogel implant composed of dextran and hyaluronic acid conjugates that form a resorbable scaffold when injected. The hydrogel enables natural restoration of tissue defects by creating an environment conducive to cell regrowth that proceeds towards the restoration of smooth hyaline cartilage. 

Visit website.

Pindari, developed by IMRA Surgical, offers a range of synthetic surgical training models designed to replicate human tissue properties. Crafted by surgeons and engineers, these models are intended for use in the operating theatre to simulate procedures such as port placement, hernia repair, and robotic surgeries. The products are cruelty-free and reusable, providing realistic responses to suturing, electro-cautery, and stapling. IMRA aims to replace the use of cadavers and animals in surgical training with high-fidelity synthetic tissue models.​

Visit website.

INEX Innovate develops molecular diagnostic tests focused on women’s and fetal health. Its product portfolio includes tests for early detection of ovarian and breast cancers, as well as non-invasive prenatal testing. These diagnostics are designed for clinical use and are processed through INEX’s subsidiary, iGene Laboratory, which is equipped for next-generation sequencing and genomic analysis. The company’s tests aim to support earlier and more accurate medical decision-making.

Visit website.

InkSpace Imaging pioneers a transformative printed electronics platform, initially prioritizing advanced MRI receive coils. These lightweight and flexible coils not only elevate diagnostic imaging, revealing the once invisible, but also expedite scans, enhance patient experiences, reduce the need for sedation, and minimize procedures. Compatible with existing MRI systems and healthcare reimbursement structures, the company's FDA-cleared innovation represents a next-generation approach to accessible, high-quality diagnostics.

Visit website.

Innitius develops a non-invasive diagnostic platform based on torsional waves to improve decision-making in obstetrics. The company’s first application focuses on the accurate diagnosis of threatened preterm labor, helping to reduce unnecessary hospital admissions and optimize care. Additional clinical indications include induction of labor and cervical assessment throughout pregnancy for preterm labor risk prevention.

Visit website.

LearUp is a cloud-based workflow automation platform designed for small and mid-sized life sciences companies. The platform streamlines project management by integrating tools for remote team collaboration, milestone tracking, and budget oversight. LearUp's solution aims to enhance operational efficiency and support digital execution across various organizational functions.

Visit website.

LIMIS is developing PerfusiX Imaging, a dye-free surgical visualization system using Laser Speckle Contrast Imaging (LSCI) to assess tissue perfusion in real time with any existing laparoscopy tower. The company is preparing for FDA 510(k) and CE-MDR submission and is actively raising funding to accelerate certification, production and strategic integration with major MIS & RAS OEMs.

Visit website.

LIQID Medical is a clinical stage medical device company pioneering the next revolution in ocular implants to treat glaucoma, the leading cause of irreversible blindness worldwide. The QMAX devices is the first-ever glaucoma device to shunt excess ocular fluid into a naturally fluid-filled space around the optic nerve. By utilizing this biological fluid reservoir, the QMAX provides unmatched glaucoma control with none of the costs and complications associated with existing devices.

Visit website.

LiveMetric develops a wrist-worn wearable device for continuous, calibration-free blood pressure monitoring. The FDA- and CE-cleared system captures arterial pressure waveforms at 100Hz, enabling real-time insights into cardiac output, heart rate, and stroke volume. Designed for remote monitoring and long-term cardiovascular care, the device provides ICU-level data without the need for traditional cuffs. LiveMetric supports scalable access to heart health information for patients, providers, and healthcare systems.

Visit website.

LuSeed's DOME is a minimally invasive device for treating bifurcation and sidewall brain aneurysms simply and effectively. The device utilizes a braided mesh design that makes it position-agnostic within the aneurysm. Another benefit of the DOME device is its design, which minimizes protrusion to the parent artery, thereby mitigating the need for dual anticoagulation therapy.

Visit website.

Maculaser develops technology to treat common retinal diseases, with a focus on age-related macular degeneration (AMD)—the leading cause of blindness in the developed world. Our proprietary platform delivers precise, non-damaging thermal stimulation to retinal tissue through controlled sub-threshold heating. This approach aims to achieve therapeutic effects that have eluded the field for over 30 years—advancing a solution long considered out of reach.

Visit website.

magAssist is an innovative medical device company specializing in heart failure treatment and circulatory support. Its main products include an interventional artificial heart for PCI procedure protection, recognized with the U.S. FDA Breakthrough Device Designation, a high-flow, long-duration extracorporeal magnetic levitation heart for acute cardiogenic shock, and a magnetic levitation ECMO system.

Visit website.

Medulla Pro develops technology to support guided needle insertion procedures, with the goal of improving accuracy and reducing complications. The company’s solutions are designed for use in lumbar puncture and nerve block procedures, offering enhanced precision for clinicians and better outcomes for patients. Medulla Pro is focused on making guided procedures the standard of care through the application of advanced engineering.

Visit website.

Meracle’s Whizz is an intuitive inhalation-management device that optimizes medication delivery to the lungs and captures real-time intake data to inform treatment assessments. By simultaneously addressing both technique and adherence—the two factors that hinder roughly 70% of respiratory patients—the Whizz stands alone in the market. In clinical trials, users achieved a three-fold improvement in asthma control versus standard care, a 90% reduction in rescue-medication use and measurable gains in quality of life.

Visit website.

Nanoflex Robotics is developing next-generation, remote robotic solutions to enhance access to life-saving procedures. The company's robotic system uses advanced magnetic technology and ultra-flexible endoluminal tools to enable faster and easier navigation through tortuous blood vessels. Nanoflex's initial target application aims to shorten the time to treatment for acute ischemic stroke by making remote mechanical thrombectomies a reality.

Visit website.

Neurosom™ is developing medical devices that integrate real-time sleep assessment with personalized therapy to support restorative health. The company’s Sleep WISP system is a wearable headband that uses EEG and machine learning to monitor sleep cycles and apply painless electrical stimulation to promote sleep onset and enhance deep sleep. Designed for home use, the system enables users to engage in sleep therapy without clinical oversight. Neurosom™ aims to advance the field of sleep through non-invasive, technology-driven solutions.

Visit website.

Nevent develops tools to improve safety in vascular access procedures. Its primary product, the NEVENT Safety Sheath, is a patented device designed to prevent the unintended retention of guidewires during catheter-based interventions. Developed by an anesthesiologist, the sheath incorporates a capture mechanism that aims to reduce the risk of complications associated with retained guidewires. Nevent's mission is to engineer out human error in vascular access, thereby improving patient outcomes and operational efficiency in healthcare settings.

Visit website.

NICE Surgical is pioneering a laparoscopic purse-string suturing device for colorectal surgery. The single-use device enables surgeons to automatically form purse-string suture, resect tissue and sealing diseased colon/rectum tissue in one swift action. The device streamlines the complex colorectal procedure and more importantly makes true intracorporeal anastomosis without extraction incision more accessible for all colorectal surgeons.

Visit website.

NousQ is a Singapore-based company focused on developing patient-centric medical technologies. Its primary product, CLiKX, is a robotic, fully automated, and sensor-optimized handheld applicator designed for ventilation ear tube surgery. CLiKX aims to simplify the procedure by reducing the need for general anesthesia and the surgical microscope, allowing surgeries to be performed in outpatient settings. The device is designed to enhance precision and safety, potentially reducing costs and improving access to care for patients with otitis media effusion.

Visit website.

Novuson’s patented DTU technology will represent the first substantive innovation in over 25 years for targeting vessel sealing / dividing, and hemostasis (bleeding control) in surgical and trauma applications.

Visit website.

OncoRes Medical is a clinical stage company developing a novel imaging modality (QME) that generates microscale maps of tissue stiffness, enabling identification of residual cancer inside the surgical cavity and complete tumour clearance. This advanced imaging technology, focused on breast cancer conserving surgery first, is broadly applicable across the 17 million solid tumours diagnosed globally and can be incorporated into minimally invasive and robotic surgical tools.

Visit website.

Onera Health is advancing sleep diagnostics through its patch-based technology designed for clinical and at-home use. The company’s solutions provide comprehensive sleep data to physicians, helping optimize care for patients with sleep-related conditions. By enabling more accessible and efficient testing, Onera supports improved outcomes while reducing overall healthcare costs.

Visit website.

Optheras A/S is a Danish medtech company headquartered in Birkerød, established in June 2022. The company specializes in developing laser-based technologies for the treatment of superficial bladder cancer, focusing on photothermal coagulation to target and treat non-invasive tumors. Their innovative approach aims to provide less invasive, low-pain alternatives to traditional surgical procedures, enabling treatments in office settings rather than operating rooms.

Visit website.

Our Xauron Perfusion System monitors real-time foot tissue perfusion changes during angioplasty procedures that restore adequate blood flow to the feet.  This fills a critical technology gap in the operating room that forces physicians to rely solely on subjective interpretation of X-ray angiographic images that can be misleading.  Our device provides precision data to elevate on-table decision-making, and to objectively evaluate the success of a procedure.  This improves the patient's prognosis for limb salvage, avoiding the cost and trauma of amputation.

Visit website.

PreciX offers advanced, non-invasive and portable devices for precise knee mobility assessments, enhancing orthopedic treatment and care.

Visit website.

PURMX Therapeutics is developing novel nucleic acid medicines using proprietary small RNA-based technologies designed to modulate multiple gene targets. The company’s lead candidate, MIRX002, is a microRNA-based therapy for malignant pleural mesothelioma, currently being evaluated in investigator-initiated clinical trials at Hiroshima University Hospital. PURMX has also initiated a sponsor-led trial in Japan for head and neck squamous cell carcinoma (HNSCC). The company is preparing for global Phase 1/2 trials to advance both indications.

Visit website.

QuantumTX is a Medtech Spin-off from the National University of Singapore bringing to market the first “Digital switch for exercise”. Their patented QMT medical device activates patient’s muscle and mitochondria in short 10-minute sessions, and recreates the benefits of aerobic exercise without physical strain. QMT devices have been indicated for improving frailty and mobility, and the company is investing into trials to further validate its benefits in managing metabolic health. 

Visit website.

Riff Medical is a pioneering Chinese medtech startup dedicated to advancing IVL therapy for the treatment of both severe and symptomatic moderate aortic stenosis. Using IVL pretreatment for calcification before TAVR may reduce complications and improve prognosis. In patients who are excluded from TAVR, IVL can help restore aortic valve function, enhance blood flow, and relieve symptoms.

Rosalind Dx is an early-stage diagnostics company advancing accessible prenatal testing (NIPT). We’re developing a dPCR-based test that can be run in any dPCR-enabled diagnostics lab – opening the door for thousands of labs to offer NIPT for the first time. Our proprietary technology overcomes key limitations of dPCR, including multiplexing constraints and target bias, enabling a path towards truly accessible, high-quality prenatal testing. 

Visit website.

SDIP Innovations is an Australian-based medical device manufacturing company. SDIP`s scaffolds and implants, JAZBI™, provide a natural healing environment for bone repair and replacement. JAZBI™ is a tissue engineering platform developed by scientists and clinicians who have established a strong reputation among surgical networks. Our primary focus is on pre-shaped bone fillers (JAZBI™ Filler) and a patent-specific flowable Kit (JAZBI™ Delivery Kit) as the initial indications for use, addressing a significant need in the $3.2B bone filler market. 

Visit website.

Solenic Medical is developing a non-invasive medical device that utilizes alternating magnetic fields to eradicate biofilms that form on implants. The company's platform uses external magnetic coils to destroy infective biofilms on the surface of knee and hip replacement implants, as well as plates and rods for trauma related procedures. Solenic's solution is being developed to replace the expensive and risky two-step revision surgery, which is the current standard of care for chronic infections on medical implants.

Visit website.

SurgiBox Inc. develops technology to improve surgical safety for both patients and healthcare providers, particularly in resource-limited settings. The company’s flagship product, SurgiBox, is designed to reduce intraoperative contamination of incisions while minimizing provider exposure to bodily fluids and aerosols. SurgiBox redefines surgical safety by focusing protection on the surgical field rather than the entire operating room. The company continues to develop a pipeline of products aimed at enabling safe and efficient surgical care in diverse environments.

Visit website.

SyMap Medical Ltd develops innovative device-based therapies targeting cardiovascular and pulmonary diseases, including hypertension, heart failure, arrhythmia, severe asthma, and early-stage lung cancer. The company received regulatory approval from the NMPA for the world’s first mapping/selective renal denervation (msRDN) system for uncontrolled hypertension, underscoring its leadership in the field. SyMap is currently advancing its second-generation, multi-electrode, computing-assisted msRDN system into clinical trials in China, Europe, and the United States.

Visit website.

Synergia Medical is developing an optoelectronic neural stimulation platform designed to enhance therapy precision and adaptability. By providing real-time feedback on stimulation effects, the technology allows for personalized treatment adjustments to improve patient outcomes. Additionally, the platform is designed to minimize MRI-related constraints, enabling a broader range of imaging procedures essential for diagnosis and treatment. Synergia Medical aims to advance neural stimulation therapies through innovative, patient-centered technology.

Visit website.

TendonPlus Medical is developing a device designed to prevent sutures from cutting through tendon tissue, a common cause of rotator cuff repair failure. By reducing suture-induced tearing, the technology aims to lower post-operative revision rates and improve surgical outcomes. With an estimated 300,000 rotator cuff procedures performed annually in the U.S. and failure rates reaching up to 40% within a year, the need for improved tendon repair solutions is significant. TendonPlus is a portfolio company of Trendlines Medical Singapore.

Visit website.

​Tensor Surgical develops the TransOs Tunneler System, an anchorless approach to rotator cuff repair and biceps tenodesis. This technique utilizes transosseous suturing to restore the native tendon-bone interface, aiming to enhance biological healing and reduce complications associated with suture anchors. The system is designed to simplify surgical workflows, reduce postoperative pain, and lower procedural costs. Tensor Surgical offers comprehensive training programs to support the adoption of this technique among orthopedic surgeons.​ 

Visit website.

Thorasys Thoracic Medical Systems Inc. is a Montreal-based company specializing in respiratory diagnostic technologies. Its primary product, the tremoflo® C-100 Airwave Oscillometry System™, assesses lung function by applying a gentle oscillatory wave during normal breathing, requiring minimal patient effort. The device is designed for use across various age groups and clinical settings, including pediatrics and remote communities.

Visit website.

Trisail Medical is a Singapore-based company focused on developing medical devices for cardiovascular conditions. The company is dedicated to advancing solutions for tricuspid regurgitation, a heart valve disorder affecting millions globally. Trisail Medical's flagship product is a minimally invasive transcatheter repair device designed to address this condition.

Visit website.

UltraSight's purpose is to make accurate cardiac ultrasound more accessible. The company's AI-driven software provides real-time guidance and quality assessment to healthcare providers, regardless of sonography proficiency. The software will make it possible to deliver this important diagnostic capability to community hospitals, ambulances, and remote and rural areas.

Visit website.

​Vantis Vascular develops advanced tools for complex coronary and peripheral interventions. Its flagship product, the CrossFAST Integrated Microcatheter Advanced Delivery System, features DuoPro™ Interlocking Technology, coupling the microcatheter and outer catheter to enhance pushability and navigation. Designed for challenging anatomies, the system aims to improve procedural efficiency and safety. Currently available in the U.S. under a limited market release, a full launch is planned for 2025.

Visit website.

VeinTech is an Australian medical technology company developing solutions to improve the accuracy and efficiency of intravenous (IV) cannulation. The company’s VeinWise System uses patented ultrasound-based technology to visualize vein pathways at depth, addressing long-standing limitations of the traditional landmark technique. Designed for ease of use and portability, the system supports clinicians in reducing insertion failures while enhancing patient comfort and clinical workflow. VeinTech’s approach aims to improve outcomes across healthcare settings by reducing complications and associated costs.

Visit website.

Vivo Surgical is pioneering the ERES™ flexible endoscopic robot for advanced endoluminal surgeries in the gastrointestinal tract. Uniquely designed to integrate seamlessly with all existing endoscopes as a robotic add-on, ERES™ leverages standard endoscopic tools whilst enabling robotic automation for enhanced precision and control. The system is intuitive and easy to use, enabling even novice users to perform advanced endoscopic procedures with minimal training.

Visit website.

Vortex Imaging is developing a novel medical imaging device that provides full volumetric (3D), operator-independent, cost-effective ultrasound imaging at the point-of-care. Vortex’s solution rapidly acquires and reconstructs images using cloud computed algorithms to produce 3D, CT-like images in minutes for physician interpretation.

Visit website.

​Wellumio develops the Axana portable MRI system, designed to enable rapid stroke detection at the point of care. Unlike traditional MRI machines, Axana employs Pulsed Gradient Free Mapping (PGFM) technology, eliminating the need for bulky components and allowing for quick, bedside imaging. The device provides critical diagnostic information within minutes, facilitating timely treatment decisions during the crucial "golden hour" following a stroke. Wellumio is conducting clinical trials in Australia and has established a U.S. subsidiary to support regulatory filings and expand access to this technology.

Visit website.

The Surgical-Fiberlcok technology functions like a surgical “sewing” machine, mechanically “interlocking” the medical patch fibers into soft tissue, allowing the surgeon to attach patches in an easier, faster, and more reliable way for various clinical applications for soft-tissue repair and augmentation. The enabling device for this technology, called FiberLocker® System, received FDA clearance for rotator cuff reinforcement in December 2024.

Visit website.